AstraZeneca’s long-acting antibody (LAAB) combination granted conditional marketing approval for the treatment of COVID-19 in Thailand

AstraZeneca’s AZD7442 (tixagevimab and cilgavimab), a long-acting antibody combination (LAAB), has been granted conditional marketing approval in Thailand for the treatment of mild to moderate COVID-19 in adults and adolescents (12 years of age and older weighing at least 40 kg). This approval is in addition to the conditional marketing approval granted to LAAB by […]

thaipr.net

2 พ.ย. 65